Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Earlier this months, the company suspended clinical trials of the drug BMS-986094, citing “the emergence of a serious safety issue.” Until now, officials have stayed mum on the exact risk posed to patients.
In addition to the participant who died, eight others were hospitalized due to adverse reactions to the drug. Bristol-Myers is investigating what caused the hospitalizations, though heart and kidney toxicity could be a factor.
More Articles on Patient Safety:
Kansas Healthcare Providers Partner for Infection Prevention Education
Loyola University Receives Grant for Infection Prevention Education
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
